Indivior Pharmaceuticals (INDV) Price to Sales (2024 - 2026)

Indivior Pharmaceuticals has reported Price to Sales for 3 years, with the latest figure at 14.12 in Q2 2026.

• On a quarterly basis, Price to Sales rose 131.81% year-over-year to 14.12 in Q2 2026; TTM through Jun 2026 was 3.64, a 132.05% increase from a year earlier, with the FY2025 full-year figure at 3.62, up 177.68% from the prior year.
• Price to Sales was 14.12 for Q2 2026 at Indivior Pharmaceuticals, up from 11.72 in the prior quarter.
• The five-year high for Price to Sales was 14.12 in Q2 2026, with the low at 4.19 in Q3 2024.
• Average Price to Sales over 3 years is 8.54, with a median of 8.43 recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Price to Sales sank 56.42% in 2025, then soared 162.25% in 2026.
• Over 3 years, Price to Sales stood at 5.18 in 2024, then jumped by 141.88% to 12.53 in 2025, then gained by 12.62% to 14.12 in 2026.
• The last three Price to Sales figures came in at 14.12 (Q2 2026), 11.72 (Q1 2026), and 12.53 (Q4 2025), per Business Quant data.